Arsela Prelaj, Medical Oncologist and PhD in Bioengineering at IRCCS Foundation National Cancer Institute, shared a post on LinkedIn:
“Today at IRCCS Foundation National Cancer Institute we had the opportunity to attend the presentation of projects funded under the Lines of Research grants, with a special focus on cancer immunotherapy.
This internal meeting brought together clinicians and researchers from across disciplines to discuss innovative ideas, early results, and translational perspectives aimed at advancing cancer care.
The program featured exciting talks on:
• Tracing anti-cancer immunity in patients undergoing liver transplantation for HCC after immunotherapy
• The role of ZEB1 in suppressive neutrophils and neutrophil extracellular traps in non-small cell lung cancer
• Roadmap for successful clinical development of bispecific antibodies and CAR-T therapies
• Interplay between tumor genotypes, immune environment, and CAR T-cell failure in large B-cell lymphoma
• Translational correlates of response to anti-PD1/anti-EGFR in cutaneous squamous cell carcinoma using ex-vivo 3D platforms
• Discovery of biomarkers for immune checkpoint blockade in pleural mesothelioma
Bladder Cancer and Non invasive Understanding tumor and immune dynamics and predicting poor outcome to intravescical therapies (beg) in patients with non-muscle-invasive bladder cancer (nmibc) that had progressed in locally/advanced metastatic disease.
These sessions not only highlighted cutting-edge science but also fostered collaboration within INT, creating fertile ground for the development of future projects.
It was inspiring to see how our institute continues to invest in internal research lines to strengthen innovation, empower young investigators, and accelerate translation into patient benefit WITHIN ACDEMIC no profit grants.”
More Posts Featuring IRCCS Foundation National Cancer Institute.
